1. Indonesia Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
PT Mustika Ratu Tbk

PT Mustika Ratu Tbk

IIDX:MRAT
406.00
IDR
+6.00
(+1.50%)
7.11EPS
49.30P/E
189.18BMarket Cap
PT Mustika Ratu Tbk
IDX:MRAT
(Indonesia Stock Exchange)

Recent

price

406.00

P/E

ratio

49.30

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
IDR
863
949.34
1,070.55
836.75
1,015.76
1,000.22
804.58
805.32
702.27
713.14
743.95
763.54
666.3
702.33
779.35
989.53
1,191.06
Revenue per Share
57.05
65.11
71.85
-15.66
16.48
2.44
-12.97
-3.08
-5.27
0.31
-15.81
0.84
158.49
-33.04
-11.97
0.97
8.97
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
9.82
11.41
16.28
16.52
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
788.58
837.42
901.58
868.21
885.38
880.87
862.33
856.74
859.64
861.19
799.94
801.75
961.12
938.88
1,340.15
1,341.7
1,350.51
Book Value per Share
788.58
837.42
901.58
868.21
885.38
880.87
862.33
856.74
859.64
861.19
799.94
801.75
929.18
919.97
1,333.34
1,325.08
1,335.2
Tangible Book Value per Share
428
428
428
428
428
428
428
428
428
428
428
428
428
428
428
428
428
Basic Weighted Avg Shares
369,366
406,316
458,197
358,128
434,747
428,093
344,361
344,679
300,573
305,225
318,408
326,795
285,178
300,596
333,563
423,517
509,772
Sales/Revenue/Turnover
10.03
9.45
9.66
-4.09
4.08
2.36
0.43
1.65
2.89
2.94
4.39
4.43
-34.87
-0.31
0.78
0.8
1.39
Operating Margin (%)
- -
5,146
5,993
5,994
6,265
5,418
4,263
4,109
4,142
3,010
2,463
2,851
2,632
2,921
2,643
2,857
3,015
Depreciation Expense
24,419
27,868
30,751
-6,700
7,055
1,046
-5,549
-1,320
-2,257
131
-6,766
358
67,833
-14,140
-5,123
416
3,838
Net Income, GAAP
25.92
24.11
27.73
- -
28.95
53.63
- -
- -
220.21
94.57
209.51
95.29
- -
- -
511.6
83.86
49.68
Effective Tax Rate (%)
6.61
6.86
6.71
-1.87
1.62
0.24
-1.61
-0.38
-0.75
0.04
-2.13
0.11
23.79
-4.7
-1.54
0.1
0.75
Profit Margin (%)
251,385
272,655
294,234
262,521
272,427
278,090
278,860
277,449
259,402
269,776
236,775
243,716
350,576
345,108
334,536
371,507
367,481
Working Capital
600
754
748
1,227
2,810
1,329
244
49
629
310
170
966
29,655
27,114
16,861
3,728
678
LT Debt
337,524
358,429
385,887
371,607
378,955
377,026
369,089
366,731
367,974
368,642
342,419
343,196
411,386
401,891
573,655
631,647
634,753
Total Equity
8.14
7.53
7.8
- -
2.13
0.61
- -
- -
-2.15
0.12
-3.34
0.18
- -
- -
-6.49
0.22
1.04
Return on Invested Capital (%)
7.54
8.06
8.33
- -
2.3
0.68
- -
- -
-2.39
0.12
-3.3
0.17
- -
- -
-10.29
0.38
1.61
Return on Capital (%)
7.47
8.01
8.26
-1.77
1.88
0.28
-1.49
-0.36
-0.61
0.04
-1.9
0.1
17.98
-3.48
-1.05
0.07
0.67
Return on Common Equity (%)

Capital Structure

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
120,915
120,413
116,788
LT Borrowings
2,500
- -
- -
LT Finance Leases
1,228
676
678
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
428
428
428
Market Capitalization
209,720
179,760
189,176

Working Capital

IDR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
579,312
564,108
572,644
Cash, Cash Equivalents & STI
175,039
172,250
171,508
Accounts Receivable, Net
127,049
116,283
132,013
Inventories
229,171
225,661
218,483
Total Current Liabilities
207,805
196,362
205,163
Payables & Accruals
- -
- -
- -
ST Debt
120,915
120,413
116,788
Deferred Revenue
- -
- -
- -

Growth Rates

IDR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.13%
14.13%
10.11%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
1,244.36%
3,688.6%
-108.12%
Sales/Revenue/Turnover
0.69%
6.65%
26.97%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
76,409
91,932
54,797
110,425
333,563
2025
85,377
104,607
69,174
164,360
423,517
2026
123,731
152,507
- -
- -
- -

Quarterly Earnings Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.37
0.34
-0.16
-12.51
-11.97
2025
0.62
0.29
0.1
-0.04
0.97
2026
2.61
6.29
- -
- -
- -

Quarterly Dividends Per Share

IDR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
PT Mustika Ratu Tbk engages in the manufacturing and marketing of herbal-based healthcare and beauty products in Indonesia. The company offers a wide range of core products and services, including jamu traditional herbal medicines under brands such as Mustika Ratu and Sidomuncul; cosmetics and skincare lines like Putri; personal care items encompassing shampoos, soaps, and body lotions; health supplements and tonics; as well as spa and wellness services through its chain of Mustika Ratu Spa outlets. These offerings target consumer markets focused on natural, traditional Indonesian remedies and modern beauty solutions, with operations primarily in Indonesia and select exports to Asia and beyond. Founded in 1972 and headquartered in Jakarta, Indonesia, PT Mustika Ratu Tbk lists its shares on the Indonesia Stock Exchange under the ticker MRAT.JK. The company operates through segments including healthcare products, cosmetics, personal care, and services, serving retail consumers, pharmacies, and spa customers across domestic markets with international distribution in countries like Malaysia, Singapore, and the Middle East. In recent developments within the last 1-2 years, PT Mustika Ratu Tbk has pursued strategic expansions, including enhanced digital marketing initiatives and e-commerce platform integrations to boost online sales amid post-pandemic recovery. The company announced new product launches in herbal immunity boosters and sustainable packaging lines in 2024, alongside partnerships with local distributors for wider archipelago coverage. Additionally, it underwent operational restructuring to optimize supply chains and reduce costs, reporting improved financial performance in its latest quarterly results as of Q3 2025.